Meghan G Haney
Overview
Explore the profile of Meghan G Haney including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
29
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Al-Hamaly M, Cox A, Haney M, Zhang W, Arvin E, Sampathi S, et al.
Biomed Pharmacother
. 2023 Dec;
170:116013.
PMID: 38104416
The Wnt/β-catenin pathway's significance in cancer initiation, progression, and stem cell biology underscores its therapeutic potential. However, the clinical application of Wnt inhibitors remains limited due to challenges posed by...
2.
Al-Hamaly M, Cox A, Haney M, Zhang W, Arvin E, Sampathi S, et al.
bioRxiv
. 2023 Sep;
PMID: 37693603
Highlights: Zebrafish-based drug screening offers an inexpensive and robust platform for identifying compounds with high efficacy and low toxicity . Erlotinib, an Epidermal Growth Factor Receptor (EGFR) inhibitor, emerged as...
3.
Sampathi S, Chernyavskaya Y, Haney M, Moore L, Snyder I, Cox A, et al.
Front Oncol
. 2023 Jan;
12:958673.
PMID: 36591474
Background: Acute Lymphoblastic Leukemia (ALL) is the most common pediatric cancer, and patients with relapsed ALL have a poor prognosis. Detection of ALL blasts remaining at the end of treatment,...
4.
Haney M, Wimsett M, Liu C, Blackburn J
STAR Protoc
. 2021 Apr;
2(2):100433.
PMID: 33889852
Dysregulation of Wnt signaling is a hallmark of many cancers, and the development of effective, non-toxic small-molecule Wnt inhibitors is desirable. Off-target toxicities of new compounds are typically tested in...
5.
Zhang W, Sviripa V, Xie Y, Yu T, Haney M, Blackburn J, et al.
iScience
. 2020 Dec;
23(12):101795.
PMID: 33305174
Aberrant activation of Wnt signaling triggered by mutations in either () or (β-catenin) is a hallmark of colorectal cancers (CRC). As part of a program to develop epigenetic regulators for...
6.
Haney M, Moore L, Blackburn J
J Vis Exp
. 2020 Apr;
(158).
PMID: 32338651
Patient derived xenograft models are critical in defining how different cancers respond to drug treatment in an in vivo system. Mouse models are the standard in the field, but zebrafish...